Sugi Predict

Sugi Predict / Compounds / SCHEMBL1119014

SCHEMBL1119014

SCHEMBL1119014

CCCCCCC/C(=C\CCCCCCCC(=O)O)C(C)=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 9/20 0.62
▸ PPARD Q03181 9/20 0.62
▸ PPARA Q07869 9/20 0.62
▸ PTPN1 P18031 5/20 0.62
▸ FABP4 P15090 4/20 0.62
▸ TERT O14746 3/20 0.62
▸ HSD17B10 Q99714 3/20 0.62
▸ TDP1 Q9NUW8 3/20 0.62
▸ MAPT P10636 2/20 0.62
▸ BLM P54132 2/20 0.62
▸ ALOX15 P16050 2/20 0.62
▸ FABP5 Q01469 2/20 0.62
▸ KMT2A Q03164 2/20 0.62
▸ GMNN O75496 1/20 0.62
▸ USP2 O75604 1/20 0.62
▸ LMNA P02545 1/20 0.62
▸ CYP1A2 P05177 1/20 0.62
▸ POLB P06746 1/20 0.62
▸ CYP2C9 P11712 1/20 0.62
▸ APEX1 P27695 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1604033 1.00 PPARG (0.62) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL1603606 1.00 PPARG (0.62) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL1119017 1.00 PPARG (0.62) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL1603607 1.00 PPARG (0.62) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL1119181 1.00 PPARG (0.62) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL1603608 1.00 PPARG (0.62) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL1119177 1.00 PPARG (0.62) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL1119019 1.00 PPARG (0.62) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL1604031 1.00 PPARG (0.62) PPARGPPARDPPARAPTPN1FABP4
SCHEMBL1119179 1.00 PPARG (0.62) PPARGPPARDPPARAPTPN1FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790167-B2 Vinyl substituted fatty acids COMPLEXA, INC. (US) 2017-10-17 — — US claimed
WO-2023014748-A1 NITRATED FATTY ACIDS FOR THE TREATMENT OF SICKLE CELL DISORDERS Imara Inc. (US) 2023-02-09 — — WO disclosed
US-20220000824-A1 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION USING THERAPEUTICALLY EFFECTIVE ORAL DOSES OF 10-NITRO-9(E)-OCTADEC-9-ENOIC ACID Imara Inc. 2022-01-06 — — US disclosed
US-20210395184-A1 VINYL SUBSTITUTED FATTY ACIDS COMPLEXA, INC. (US) 2021-12-23 — — US disclosed
CN-113440506-A Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids 康普莱克夏公司 2021-09-28 — — CN disclosed
US-20200308096-A1 VINYL SUBSTITUTED FATTY ACIDS COMPLEXA, INC. (US) 2020-10-01 — — US disclosed
US-20200046669-A1 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION USING THERAPEUTICALLY EFFECTIVE ORAL DOSES OF 10-NITRO-9(E)-OCTADEC-9-ENOIC ACID COMPLEXA, INC. 2020-02-13 — — US disclosed
EP-3355879-A1 PREVENTION, TREATMENT AND REVERSAL OF DISEASE USING THERAPEUTICALLY EFFECTIVE AMOUNTS OF ACTIVATED FATTY ACIDS Complexa, Inc. (US) 2018-08-08 — — EP disclosed
EP-2280928-B1 VINYL SUBSTITUTED FATTY ACIDS COMPLEXA INC (US) 2018-07-25 — — EP disclosed
US-20170369419-A1 VINYL SUBSTITUTED FATTY ACIDS COMPLEXA, INC. (US) 2017-12-28 — — US disclosed
US-9790167-B2 Vinyl substituted fatty acids COMPLEXA, INC. (US) 2017-10-17 — — US disclosed
US-20170095437-A1 PREVENTION, TREATMENT AND REVERSAL OF DISEASE USING THERAPEUTICALLY EFFECTIVE AMOUNTS OF ACTIVATED FATTY ACIDS Imara Inc. 2017-04-06 — — US disclosed
US-20130012583-A1 VINYL SUBSTITUTED FATTY ACIDS UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2013-01-10 — — US disclosed
EP-2280928-A2 VINYL SUBSTITUTED FATTY ACIDS Complexa Inc. (US) 2011-02-09 — — EP disclosed
US-20090326070-A1 VINYL SUBSTITUTED FATTY ACIDS COMPLEXA INC. (US) 2009-12-31 — — US disclosed
WO-2009134383-A2 VINYL SUBSTITUTED FATTY ACIDS COMPLEXA INC. (US) 2009-11-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200046669-A1 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION USING THERAPEUTICALLY EFFECTIVE ORAL DOSES OF 10-NITRO-9(E)-OCTADEC-9-ENOIC ACID REN, ALOX5, ELOVL5 PPARG 34/4885PPARD 79/4885PPARA 18/4885
US-20170095437-A1 PREVENTION, TREATMENT AND REVERSAL OF DISEASE USING THERAPEUTICALLY EFFECTIVE AMOUNTS OF ACTIVATED FATTY ACIDS REN, ALOX5, ELOVL1 PPARG 17/4885PPARD 26/4885PPARA 11/4885
US-20200308096-A1 VINYL SUBSTITUTED FATTY ACIDS FFAR2, ELOVL1, FFAR4 PPARG 15/4885PPARD 35/4885PPARA 12/4885
US-20170369419-A1 VINYL SUBSTITUTED FATTY ACIDS FFAR2, ELOVL1, FFAR4 PPARG 15/4885PPARD 35/4885PPARA 12/4885
US-20130012583-A1 VINYL SUBSTITUTED FATTY ACIDS FFAR2, ELOVL1, FFAR4 PPARG 15/4885PPARD 35/4885PPARA 12/4885
US-20220000824-A1 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION USING THERAPEUTICALLY EFFECTIVE ORAL DOSES OF 10-NITRO-9(E)-OCTADEC-9-ENOIC ACID REN, ALOX5, ELOVL5 PPARG 34/4885PPARD 79/4885PPARA 18/4885
US-20210395184-A1 VINYL SUBSTITUTED FATTY ACIDS FFAR2, ELOVL1, FFAR4 PPARG 15/4885PPARD 35/4885PPARA 12/4885
US-20090326070-A1 VINYL SUBSTITUTED FATTY ACIDS FFAR2, ELOVL1, FFAR4 PPARG 15/4885PPARD 35/4885PPARA 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.